Osseon announced U.S. Food and Drug Administration clearance and the commercial release of its Osseoflex SB 2ml steerable balloon, an addition to its articulating vertebral augmentation product line.
The steerable Osseoflex SB balloon can navigate with accuracy and control within the vertebra to create a central cavity across the sagittal midline.
Osseon focuses on developing and commercializing medical devices for minimally invasive treatment of vertebral compression fractures.
More articles on devices:
Ronda Stryker sells 14k more shares in $1M transaction
Who has clinical quality & cost-effectiveness in spine? Frost & Sullivan says Baxano
LDR COO sells 19k shares in $512k transaction